Vijaya Diagnostics Q1 FY27 Results: Revenue Rs 230 Cr, PAT Rs 53 Cr and Key Highlights

Vijaya Diagnostics Q1 FY27 results were announced on August 6, 2026, on a Consolidated basis. Vijaya Diagnostics Q1 FY27 results show revenue grew +22.83% year-on-year to Rs 230 Cr from Rs 188 Cr in Q1 FY26, reflecting sustained demand in the Healthcare segment. The broader BSE Healthcare index also reflected mixed sentiment during the quarter.

Operating profit improved +39.46% YoY to Rs 73 Cr from Rs 52 Cr, indicating stronger operational efficiency. PAT rose +37.61% YoY to Rs 53.00 Cr from Rs 38.00 Cr in Q1 FY26. The quarterly numbers offer a detailed picture of how the company is navigating the current healthcare environment.

Click Here – Get Free Investment Predictions

Vijaya Diagnostics Q1 FY27 Financial Highlights

Metric	Q1 FY27 (Rs Cr)	Q1 FY26 (Rs Cr)	YoY Change
Vijaya Diagnostics Revenue	230	188	+22.83%
Operating Profit	73	52	+39.46%
Net Profit (PAT)	53	38	+37.61%
Reporting Basis	Consolidated

Vijaya Diagnostics Q1 FY27 Performance Analysis

Check the Univest Screener for Live Data on This Stock

Vijaya Diagnostics Q1 FY27 results reflect healthy fundamentals across key financial parameters. Revenue momentum continued on a strong footing with the top line reaching Rs 230 Cr for the April to June 2026 quarter.

Operating profit stood at Rs 73 Cr, expanding +39.46% YoY. Margin improvement signals better cost absorption and product mix optimisation.

PAT of Rs 53 Cr marks a +37.61% year-on-year improvement. Investors monitoring Vijaya Diagnostics Q1 FY27 results will note this as a key milestone for FY27 tracking.

Key Business Factors in Vijaya Diagnostics Q1 FY27 Results

Revenue Growth Momentum in the Healthcare Segment

Vijaya Diagnostics Q1 FY27 results demonstrate consistent top-line expansion, with revenue rising +22.83% YoY to Rs 230 Cr. Volume-led growth and pricing discipline in key markets drove the uptick.

Operating Margin Expansion Signals Efficiency Gains

Operating profit in Vijaya Diagnostics Q1 FY27 results rose +39.46% YoY to Rs 73 Cr. This reflects tighter cost control, better product mix, and operating leverage as the company scales volumes in core business lines.

PAT Performance and Profitability Trend

Net profit in Vijaya Diagnostics Q1 FY27 results stood at Rs 53 Cr (+37.61% YoY). The sustained PAT growth reflects the company's improving financial profile.

Dividend Details

No dividend was announced along with Vijaya Diagnostics Q1 FY27 results. The company is likely retaining earnings for reinvestment into growth capex and working capital requirements.

FY27 Outlook for Vijaya Diagnostics

Vijaya Diagnostics is positioned to maintain growth momentum into Q2 FY27 and beyond, supported by order visibility, operational improvements, and sector tailwinds. Management guidance points toward continued expansion in the Healthcare business with a focus on margin improvement and market share consolidation. Investors tracking Vijaya Diagnostics Q1 FY27 results are advised to consult a SEBI-registered financial advisor before making decisions.

Vijaya Diagnostics Stock Performance After Q1 FY27 Results

Download the Univest iOS App or Univest Android App to track Vijaya Diagnostics live price and get daily stock recommendations.

Vijaya Diagnostics shares were trading lower at Rs 1369.8 (-1.42%) on August 6, 2026, following the declaration of Vijaya Diagnostics Q1 FY27 results. The stock reaction reflects investor sentiment on near-term earnings trajectory and sector outlook. CMP stood at Rs 1369.8 on the results date, with a 52-week range reflecting the broader market sentiment toward the healthcare sector.

Key Risks for Vijaya Diagnostics

Sector-Specific Headwinds

Rising operational costs, competition from hospital chains, and insurance penetration risks could limit upside.

Valuation and Earnings Risk

Valuation risk remains if earnings growth fails to sustain at current levels over the next two to three quarters.

Operational and Financial Risk

Subsidiary-level losses or underperformance in overseas operations could drag consolidated PAT lower.

Conclusion

Vijaya Diagnostics Q1 FY27 results demonstrate healthy financial performance with revenue at Rs 230 Cr and PAT at Rs 53 Cr on a Consolidated basis. Operating leverage and disciplined cost management will be key drivers for the rest of FY27. Investors should track upcoming management commentary on growth drivers and sector developments before taking positions.

Frequently Asked Questions on Vijaya Diagnostics Q1 FY27 Results

When were Vijaya Diagnostics Q1 FY27 results declared?

Ans. Vijaya Diagnostics Q1 FY27 results were declared on August 6, 2026. The results cover the April to June 2026 quarter on a Consolidated basis.

What was Vijaya Diagnostics revenue in Q1 FY27?

Ans. Vijaya Diagnostics Q1 FY27 results show revenue of Rs 230 Cr, +22.83% compared to Rs 188 Cr in Q1 FY26.

What was Vijaya Diagnostics PAT in Q1 FY27?

Ans. Net profit (PAT) in Vijaya Diagnostics Q1 FY27 results was Rs 53 Cr, +37.61% year-on-year.

Did Vijaya Diagnostics declare a dividend in Q1 FY27?

Ans. No dividend was declared alongside Vijaya Diagnostics Q1 FY27 results. Investors should check the official company announcements on BSE and NSE for any future dividend declarations.

What is the FY27 outlook for Vijaya Diagnostics?

Ans. Vijaya Diagnostics management has outlined a focus on revenue scaling and margin improvement for the remainder of FY27. Sector tailwinds and order book visibility will be key monitorables.

How did the Vijaya Diagnostics stock react to Q1 FY27 results?

Ans. Vijaya Diagnostics shares were trading lower at Rs 1369.8 (-1.42%) on August 6, 2026, following the Vijaya Diagnostics Q1 FY27 results announcement. Investors should consult a SEBI-registered financial advisor before acting on price movements.